Collegium Pharmaceutical, Inc. Forecast, price target & analysts
Collegium Pharmaceutical, Inc. Target price 2025 - Analyst rating & recommendation
Collegium Pharmaceutical, Inc. Classifications & Recommendation:
Collegium Pharmaceutical, Inc. Price Target
| Target Price | $42.84 |
| Price | $32.52 |
| Potential |
31.73%
register free of charge
|
| Number of Estimates | 7 |
|
7 Analysts have issued a price target Collegium Pharmaceutical, Inc. 2026 .
The average Collegium Pharmaceutical, Inc. target price is $42.84.
This is
31.73%
register free of charge
$52.50
61.44%
register free of charge
$37.37
14.91%
register free of charge
|
|
| A rating was issued by 11 analysts: 9 Analysts recommend Collegium Pharmaceutical, Inc. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Collegium Pharmaceutical, Inc. stock has an average upside potential 2026 of
31.73%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2030
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 631.45 | 759.16 |
| 11.41% | 20.22% | |
| EBITDA Margin | 53.70% | 58.72% |
| 6.28% | 9.36% | |
| Net Margin | 10.96% | 29.74% |
| 28.95% | 171.42% |
7 Analysts have issued a sales forecast Collegium Pharmaceutical, Inc. 2025 . The average Collegium Pharmaceutical, Inc. sales estimate is
This results in the following potential growth metrics:
7 Analysts have issued an Collegium Pharmaceutical, Inc. EBITDA forecast 2025. The average Collegium Pharmaceutical, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
7 Collegium Pharmaceutical, Inc. Analysts have issued a net profit forecast 2025. The average Collegium Pharmaceutical, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2030
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 1.71 | 7.03 |
| 48.70% | 311.11% | |
| P/E | 4.63 | |
| EV/Sales | 2.22 |
7 Analysts have issued a Collegium Pharmaceutical, Inc. forecast for earnings per share. The average Collegium Pharmaceutical, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Collegium Pharmaceutical, Inc....
Current Collegium Pharmaceutical, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Piper Sandler |
Locked
➜
Locked
|
Locked | May 09 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Apr 09 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 24 2025 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Feb 04 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 10 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Jan 10 2025 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Oct 11 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Piper Sandler:
Locked
➜
Locked
|
May 09 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Apr 09 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 24 2025 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Feb 04 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 10 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Jan 10 2025 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Oct 11 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
